Tag: CNDO

Blue Horseshoe Stocks: CNDO Recap & Much More

Esperion Therapeutics, Inc. ESPR

ESPR was an unstoppable juggernaut for us this week. On Tuesday, we floated the idea of tracking the ESPR 04/17 $90 Calls, and those contracts have gone on a wild run since then.

As the stock pushed its way to new 52-week highs yesterday, finally topped those contracts out at 28.50, it marked an overall increase of 714% from the 3.50 low we observed on Tuesday; quite an impressive feat for a span of just three sessions.

Add in the multiplicity of opportunities in short-term weekly calls that we’ve witnessed (on the order of percentage gains in the thousands!) as the stock made this historical run, and we’ll have to mark ESPR down as one of our most successful alerts thus far in 2015.

Coronado BioSciences, Inc. CNDO

CNDO did quite well following our tag of it in yesterday morning’s extended watchlist, further solidifying the notion that biopharmas have been on a real hot streak this week.

We watched as CNDO ripped its way from a daily low of 3.62 to as high as 5.35, totaling an intraday run of 48% The move came on volume which smashed the 3-month average by a factor of more than 32X Congrats to any of our readers who lassoed this momentum-mover for some tidy gains yesterday!

Amicus Therapeutics, Inc. FOLD

FOLD also appear on yesterday’s watchlist before extending its own epic run with a modest yet notable increase of 13% on the day, trading a range from 11.63-13.20. Like the previously mentioned play, this stock has also been on a blue-sky breakout, setting new annual highs with every uptick.

Morning Gappers – Options Ideas

Nike, Inc. NKE shares surged as the company beat Wall St. estimates for profits on yesterday’s earnings call, and appears to be gapping up significantly in this morning’s premaket activity. We are going to be monitoring the $101-104 Weekly Calls for potential daytrading opportunities, and for a possible a swing trade into the weeks ahead, we’ll radar the 04/10 $105-110 Calls.

Prothena Corp plc PRTA is gapping up monstrously today to the tune of 40%, soaring on yesterday’s post-market revelation of positive Phase 1 results for its treatment for Parkinson’s disease. We will be placing $35 and 40 Calls on watch for daytrading potential, while tracking the 06/19 $45 Calls for a longer-term play.

Extended Watchlist:
VBLT, SPEX, VGGL, ICLD, RNN

Blue Horseshoe Stocks: ESPR Options, MVIS Recaps & More


Esperion Therapeutics, Inc. ESPR

ESPR found new highs once again yesterday for the second straight session after we initially tagged it for options trading potential on Tuesday.

In addition to monitoring Weekly In-the-money Calls, which yielded up the opportunity at gains ranging from 400-1400% on Tuesday, and continued their own runs yesterday, we also had specified a longer-term idea that continued to work extraordinarily well.

That idea, the 04/17 $90 Calls, traded from a low of 11.60 all the way up to 21.90 yesterday. It represented an excellent single-session intraday increase of 89%, and a whopping 525% jump over our observed low from Tuesday (3.50).

Big congratulations go out to any of our readers who reaped the benefits ESPR, which has easily emerged as our top target of the week! The stock is gapping up in the premarket this morning, so it appears as if we could see a further extension of those gains.

Microvision, Inc. MVIS

On Monday we tagged MVIS in a gap-up watchlist, and it has found its way into every one of our reports this week, setting new highs each day.

Yesterday the stock traded in a range from 3.42-4.23, a healthy intraday move of 24% From our observed low of 2.88 on Monday, that high marked a rise of 47% overall.

As you can see below, given the extremely over-bought look of the chart, now might be a good time to lock in any profits gained over the course of the week. This major move has been fueled by a PR out Monday in which the company announced orders totaling more than $14M it had received for components of its patented PicoP® display technology >> VIEW PR

Side Note:

Yesterday in advance of the FOMC Meeting, we cautioned readers to stay alert and watch for the effect that Janet Yellen’s commentary would have on the markets. To take advantage of this expected surge in either direction, we mentioned trading options calls on either the SPY, if the markets went up, or UVXY and/or VIX if they slid back.  Either way it played out, we said, we wanted “to stay in-the-money with our strike prices.”

As it turned out, the Fed announcement caused a sharp rise in the markets, and as a result the SPY Calls were the ones to play. We saw substantial gains on in-the-money Calls as the SPY spiked to $211.27.

For example, the SPY $209.50 Calls traded in a range from .80-2.00, for an intraday move totaling 150%  $210 Calls also spiked heavily from a low of .40 to as much as 1.59, a huge 297% jump.

Extended Watchlist:
FOLD, RAD, NQ, CNDO, SYN, SMLR

Blue Horseshoe Stocks: Pharma Watchlist & More

Lexicon Pharmaceuticals, Inc. LXRX

We’re taking notice of LXRX this morning in the wake of a premarket PR that has the stock trending up to its highest levels of the past three months; it contained updates on current projects as well as increased earnings. The addition of an interesting setup on the chart gives us good reason to place LXRX on watch this mid-week.

As you can see on the snapshot below, the stock gapped down significantly at the end of November. In premarket activity today we’re seeing a partial fill taking place. We’re going to be watching for LXRX to fill the remainder of the gap into the mid 1.20’s where its next area of resistance will come in at the 200DMA of 1.28.

THE WOODLANDS, Texas, March 4, 2015 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2014.>> VIEW PR

Pharmaceutical Watchlist

There are a number of other pharma and biopharma stocks gapping up in the premarket this morning, some of which have appeared in our reports in the past. We’ve listed them below along with links to today’s news, where applicable:

Keryx Biopharmaceuticals, Inc. KERX


Atossa Genetics, Inc. ATOS


Coronado Biosciences, Inc. CNDO

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies (Wed 8:30AM EST)

PhotoMedex, Inc. PHMD

Orexigen Therapeutics, Inc. OREX

KaloBios Pharmaceuticals, Inc. KBIO

Earnings-Related Options Ideas

American Eagle Outfitters, Inc. AEO beat expected Q4 profits and revenues, and is gapping up as a result. To take advantage of the trend, we are monitoring options trading possibilities in the AEO Weekly $15-16 Calls

Abercrombie & Fitch ANF fell short of expectations with regard to sales, which is fueling a downtrend here in the premarket, so we’ll take the opposite approach here, and keep an eye on ANF Weekly $23-24 Puts.

Extended Watchlist:
IFON, PLUG, NPTN, WLT, LEI